AbbVie reports experimental hepatitis C trial, ‘Aviator’, cured up to 96 percent of patients

Biopharmaceutical company, AbbVie Inc announced today the results of its phase IIb clinical trial of its investigational direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) infection. Image/Video More...